BRAF-mutations in non-small cell lung cancer

被引：63

作者：

Brustugun, Odd Terje ^{[1
,2
]}

Khattak, Asma Malik ^{[3
]}

Tromborg, Anette Kjoshagen ^{[3
]}

Beigi, Marzieh ^{[3
]}

Beiske, Klaus ^{[3
]}

Lund-Iversen, Marius ^{[3
]}

Helland, Aslaug ^{[1
,2
]}

机构：

[1] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Oncol, N-0310 Oslo, Norway

[2] Univ Oslo, Inst Clin Med, Oslo, Norway

[3] Norwegian Radium Hosp, Oslo Univ Hosp, Dept Pathol, N-0310 Oslo, Norway

来源：

LUNG CANCER | 2014年 / 84卷 / 01期

关键词：

EGFR-mutation; BRAF-mutation; Genetic testing; Lung cancer; Tyrosine kinase inhibitors; ADENOCARCINOMAS; FEATURES; PATIENT;

D O I：

10.1016/j.lungcan.2014.01.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. Material and methods: NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 were tested for V600E/K BRAF-mutations using a PCR-based method. Results: We found a BRAF-mutation frequency of 1.7% in the total cohort of 979 patients, and 23% among 646 adenocarcinomas. One of the BRAF-positive samples was also KRAS-mutated, and one had an ALK-translocation. None of 231 squamous cell carcinomas were BRAF-mutated. The proportion of never-smokers among BRAF-positives was high (29%). Conclusion: BRAF-mutation analysis should be part of the subtyping of non-squamous NSCLC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：36 / 38

页数：3

共 50 条

[31] Dabrafenib in patients with BRAF-mutated non-small cell lung cancer
Kawamura, Takahisa
Murakami, Haruyasu
TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S342 - S344
[32] Ongoing Progress in BRAF-Mutated Non-Small Cell Lung Cancer
Abdayem, Pamela
Planchard, David
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (11) : 662 - +
[33] Mutation Profile of BRAF in Chinese Non-Small Cell Lung Cancer Patients
Ai, X.
Li, Y.
Chen, R.
Gu, D.
Mao, Y.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1149 - S1149
[34] BRAF Non-V600E Mutations Recurrently Found in Non-Small Cell Lung Cancer in Chinese Patients
Xu, Q.
Wang, W.
Xu, C.
Zhuang, W.
Song, Z.
Zhu, Y.
Xu, Z.
Chen, R.
Guan, Y.
Yi, X.
Chen, G.
Fang, M.
Lv, T.
Song, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1944 - S1944
[35] Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer
Kim, Young Hak
JOURNAL OF THORACIC DISEASE, 2016, 8 (09) : 2369 - 2371
[36] Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review
Chmielewska, Izabela
Krawczyk, Pawel
Wojcik-Superczynska, Magdalena
Grenda, Anna
Gil, Michal
Stencel, Katarzyna
Kieszko, Robert
Jankowski, Tomasz
Milanowski, Janusz
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (10) : 2491 - 2499
[37] PREDICTIVE VALUE OF KRAS AND BRAF MUTATIONS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH CHEMOTHERAPY
Dingemans, Anne-Marie
Smit, Egbert F.
Heideman, Danielle
Mellema, Wouter
Derks, Jules
Van, Robertjan Suylen
Thunnissen, Erik
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1044 - S1044
[38] Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors
Garcia-Illescas, D.
Callejo, A.
Iranzo, P.
Assaf, J. D.
Molina, G.
Priano, I.
Valdivia, A.
Pardo, N.
Navarro, A.
Martinez-Marti, A.
Cedres, S.
Carbonell, C.
Frigola, J.
Amat, R.
Felip, E.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S378 - S379
[39] BRAF V600E mutations: a series of case reports in patients with non-small cell lung cancer
Goldman, Jamie M.
Gray, Jhanelle E.
CANCER GENETICS, 2015, 208 (06) : 351 - 354
[40] Co-mutations of epidermal growth factor receptor and BRAF in Chinese non-small cell lung cancer patients
Peng, Panli
Lv, Guoli
Hu, Jinwei
Wang, Kai
Lv, Junhong
Guo, Gang
ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (16)

← 1 2 3 4 5 →